Asperger syndrome medical therapy
Jump to navigation
Jump to search
|
Asperger Syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Asperger syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Asperger syndrome medical therapy |
|
Risk calculators and risk factors for Asperger syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[2]
Overview
Medical treatments used in Asperger Syndrome include: stimulants, a-2 adrenergic agonists, atypical antipsychotics, antidepressants and anticonvulsants.[1] Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
Medical Therapy
- Many studies believe that medications alone can not improve Asperger Syndrome's (AS) symptoms and other complementary interventions (social and behavioral) are required.[1]
- Medications used in Asperger Syndrome (AS) include:[1]
- Stimulants such as methylphenidate and amphetamines (for comorbidity between AS and attention deficit hyperactivity disorder (ADHD))
- a-2 adrenergic agonists such as clonidine and guanfacine (treatment of aggression, anxiety and Tourette syndrome (TS) which are associated with AS)
- Atypical antipsychotics such as aripiprazole, olanzapine, ziprasidone (treatment of aggression, hallucinations, hyperactivity, irritability, anxiety, depression in AS patients)[2]
- Antidepressantssuch as selective serotonin reuptake inhibitors (SSRIs) (treatment of depressive disorders and obsessive compulsive disorder (OCD) associated with AS)
- Anticonvulsants(for aggression, mood disorders, irritability, repetitive behaviors in AS)[3]
References
- ↑ 1.0 1.1 1.2 1.3 Tarazi FI, Sahli ZT, Pleskow J, Mousa SA (2015). "Asperger's syndrome: diagnosis, comorbidity and therapy". Expert Rev Neurother. 15 (3): 281–93. doi:10.1586/14737175.2015.1009898. PMID 25655905.
- ↑ Crystal S, Olfson M, Huang C, Pincus H, Gerhard T (2009). "Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges". Health Aff (Millwood). 28 (5): w770–81. doi:10.1377/hlthaff.28.5.w770. PMC 2896705. PMID 19622537.
- ↑ Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006). "Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder". Int J Neuropsychopharmacol. 9 (2): 209–13. doi:10.1017/S1461145705005791. PMID 16316486.